Evaluation of S-RBD and high specificity ACE-2-binding antibodies on SARS-CoV-2 patients after six months from infection.
Neutralizing antibodies
S-RBD antibodies
SARS-CoV-2
Serological tests
Vaccines
Journal
International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
29
05
2021
revised:
02
07
2021
accepted:
20
07
2021
pubmed:
3
8
2021
medline:
23
9
2021
entrez:
2
8
2021
Statut:
ppublish
Résumé
The antibody response to SARS-CoV-2 has not yet fully defined, but the availability of sensitive and specific serological assays is crucial to observe the presence of specific antibodies against the human receptor binding domain (S-RBD) and high specificity ACE-2-binding antibodies or neutralizing antibodies (NT) in response to vaccines. Indeed, these peculiar antibodies should prevent viral interaction between RBD and Angiotensin-Converting Enzyme 2 (ACE2) receptor, located on surface of host cells. In this study, 72 samples from 37 hospitalized COVID-19 patients and 35 not-hospitalized patients were analyzed longitudinally. The detection of S-RBD and NT antibodies was carried out using CLIA tests. Hospitalized patients showed elevated serum levels of S-RBD (97.22%) and NT (77.78%) antibodies, differently, not-hospitalized, who were paucisymptomatic or asymptomatic patients, showed lower serum levels of S-RBD (65.71%) and NT (38.14%) antibodies. The results suggest that the NT serum level is strongly related to disease severity (p < 0.001) and to the serum level of S-RBD antibodies (p < 0.0001).
Identifiants
pubmed: 34339963
pii: S1567-5769(21)00649-4
doi: 10.1016/j.intimp.2021.108013
pmc: PMC8313542
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
108013Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Références
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Nature. 2020 Jul;583(7815):290-295
pubmed: 32422645
Nature. 2020 Aug;584(7821):450-456
pubmed: 32698192
Sci Immunol. 2020 Dec 7;5(54):
pubmed: 33288645
Clin Chim Acta. 2020 Dec;511:28-32
pubmed: 33002475
Nature. 2020 Aug;584(7819):115-119
pubmed: 32454513
J Med Virol. 2021 Apr;93(4):2160-2167
pubmed: 33064340
J Med Virol. 2020 Sep;92(9):1518-1524
pubmed: 32104917
Sci Immunol. 2020 Oct 8;5(52):
pubmed: 33033172
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
EBioMedicine. 2020 Dec;62:103101
pubmed: 33160207